Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch
Maia Kayal(Icahn School of Medicine at Mount Sinai), Edward L. Barnes(University of North Carolina at Chapel Hill), Laura E. Raffals(Mayo Clinic), Taha Qazi(Cleveland Clinic), Chelsea Anderson(University of North Carolina at Chapel Hill), Matthew D. Smyth(University of British Columbia), Raymond Cross(University of Maryland, Baltimore), Shannon Chang(NYU Langone Health), Peter Higgins(Michigan Medicine), Millie D. Long(University of North Carolina Health Care), Poonam Beniwal‐Patel(Medical College of Wisconsin), Hans Herfarth(University of North Carolina at Chapel Hill), Parakkal Deepak(Washington University in St. Louis), Elizabeth A. Spencer(Icahn School of Medicine at Mount Sinai), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai)
Cited by 8
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
|Gastroenterology|2018|1.7k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k